Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-04-30

Y-mAbs Therapeutics (YMAB)

CEO Michael Rossi was paid $4,557,590 in fiscal year 2024, ↑ up 46.5% from fiscal year 2023, the 56th percentile of its disclosed peer group (SEC filing 0001558370-25-008299 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$4,557,590 ↑
Michael Rossi total, FY2024
56th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
87.56%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Michael Rossi (President and Chief Executive Officer), FY2024 total compensation $4,557,590 (base salary $705,600) [exec_comp, SEC accession 0001558370-25-008299, filed 2025-05-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Michael Rossi$705,600$0$1,170,732$2,288,662$392,596$0$0$4,557,590
President and Chief Executive Officer
Peter Pfreundschuh252,0830573,6201,580,60998,405002,504,717
Treasurer and Chief Financial Officer
Thomas Gad579,7520213,928949,349248,134084,0002,075,163
Founder, Chief Business Officer and Vice Chairman of the Board of Directors

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Michael Rossi$4,557,590$3,110,553—↑ +1,447,037
Peter Pfreundschuh2,504,717———
Thomas Gad2,075,1632,454,483—↓ −379,320

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Y-mAbs Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper YMAB reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against YMAB
13 companies name YMAB as a compensation peer

The list of companies that name YMAB as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Peter PfreundschuhCFO$2,504,717
Michael RossiCEO$4,557,590
Thomas GadExecutive$2,075,163
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Ashutosh TyagiIndependent Director$227,792
David N. GillIndependent Director$250,292
Dr. Gérard BerFormer director (through FY2024)$40,061
James I. HealyChair of the Board$262,792
Johan Wedell-WedellsborgIndependent Director$227,792
Laura J. HamillIndependent Director$237,792
Mary TagliaferriIndependent Director$602,497
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Thomas GadDirector2025-06-03D103,000$0$0Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-06-03A103,0002206,000CommonForm 4 ↗
Ashutosh TyagiDirector2025-06-30A33,45000Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-06-30A25,08000CommonForm 4 ↗
James I. HealyDirector2025-06-30A33,45000Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-06-30A25,08000CommonForm 4 ↗
Laura J. HamillDirector2025-06-30A33,45000Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-06-30A33,45000Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-06-30A25,08000CommonForm 4 ↗
David N. GillDirector2025-06-30A33,45000Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-06-30A25,08000CommonForm 4 ↗
Laura J. HamillDirector2025-06-30A25,08000CommonForm 4 ↗
Michael RossiDirector2025-09-16D18,000——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D14,545——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D13,950——Derivative, Class A CommonForm 4 ↗
Michael RossiDirector2025-09-16D52,650——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D33,450——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D14,545——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D13,950——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D8,000——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D14,222——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D2,194,278918,870,791Common, indirectForm 4 ↗
James I. HealyDirector2025-09-16D31,6039271,786CommonForm 4 ↗
John LaRoccaSVP, General Counsel & Secry2025-09-16D42,900——Derivative, Class A CommonForm 4 ↗
John LaRoccaSVP, General Counsel & Secry2025-09-16D142,600——Derivative, Class A CommonForm 4 ↗
John LaRoccaSVP, General Counsel & Secry2025-09-16D21,500——CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D33,450——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D14,545——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D13,950——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D32,000——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D36,000——Derivative, Class A CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D4,559,233939,209,404CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D25,080——CommonForm 4 ↗
Johan Wedell-WedellsborgDirector2025-09-16D5,825950,095CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D42,900——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D35,700——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D32,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D35,700——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D20,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D32,000——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D5,825950,095CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D20,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D20,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D20,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D20,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D20,000——Derivative, Class A CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D39,301——CommonForm 4 ↗
Michael RossiDirector2025-09-16D18,000——Derivative, Class A CommonForm 4 ↗
Michael RossiDirector2025-09-16D129,101——CommonForm 4 ↗
Michael RossiDirector2025-09-16D7,982968,645CommonForm 4 ↗
Thomas GadDirector2025-09-16D91,450——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D33,450——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D32,000——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Douglas J. GentilcoreSVP, Danyelza Bus. Unit Head2025-09-16D142,600——Derivative, Class A CommonForm 4 ↗
Biotech ApS WGDirector2025-09-16D4,559,233939,209,404CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D25,080——CommonForm 4 ↗
Ashutosh TyagiDirector2025-09-16D5,825950,095CommonForm 4 ↗
Joris WilmsSVP & CHIEF OPERATING OFFICER2025-09-16D12,7999110,071CommonForm 4 ↗
Michael RossiDirector2025-09-16D52,650——Derivative, Class A CommonForm 4 ↗
Michael RossiDirector2025-09-16D18,000——Derivative, Class A CommonForm 4 ↗
Michael RossiDirector2025-09-16D210,700——Derivative, Class A CommonForm 4 ↗
Michael RossiDirector2025-09-16D214,200——Derivative, Class A CommonForm 4 ↗
Michael RossiDirector2025-09-16D615,240——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D64,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D132,500——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D75,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D242,200——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D60,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D110,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D130,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D107,500——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D100,000——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D143,169——Derivative, Class A CommonForm 4 ↗
Thomas GadDirector2025-09-16D60,0009516,000CommonForm 4 ↗
Thomas GadDirector2025-09-16D67,6819582,057CommonForm 4 ↗
Thomas GadDirector2025-09-16D60,235——CommonForm 4 ↗
Thomas GadDirector2025-09-16D245,48692,111,180CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D33,450——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D14,545——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D13,950——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D27,000——Derivative, Class A CommonForm 4 ↗
Laura J. HamillDirector2025-09-16D25,080——CommonForm 4 ↗
Peter PfreundschuhEVP, CFO and Treasurer2025-09-16D15,900——Derivative, Class A CommonForm 4 ↗
Peter PfreundschuhEVP, CFO and Treasurer2025-09-16D63,500——Derivative, Class A CommonForm 4 ↗
Peter PfreundschuhEVP, CFO and Treasurer2025-09-16D170,000——Derivative, Class A CommonForm 4 ↗
Peter PfreundschuhEVP, CFO and Treasurer2025-09-16D77,800——CommonForm 4 ↗
Peter PfreundschuhEVP, CFO and Treasurer2025-09-16D15,900——Derivative, Class A CommonForm 4 ↗
James I. HealyDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D33,450——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D14,545——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D13,950——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D11,000——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D16,000——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D24,000——Derivative, Class A CommonForm 4 ↗
David N. GillDirector2025-09-16D25,080——CommonForm 4 ↗
David N. GillDirector2025-09-16D5,825950,095CommonForm 4 ↗
James I. HealyDirector2025-09-16D25,080——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Peter PfreundschuhRSU46,000—$360,180
Thomas GadRSU27,001—211,418
Thomas GadOption126,2354.7—
Thomas GadOption54,6905.75—
Michael RossiRSU35,700—279,531
Michael RossiOption448,6345.75—
Thomas GadOption21,2889.52—
Michael RossiOption214,20014.36—
Michael RossiPSU54,000—422,820
Thomas GadRSU22,100—173,043
Thomas GadOption27,58815.73—
Thomas GadOption132,5009.83—
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's executive pay program is consistent with market and industry practice and reflects a pay-for-performance philosophy.

CEO STI target (% of salary)65%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-07-1127,011,0273,838,5651,75587.56%Passed
20242024-06-1127,772,834721,69352197.47%Passed
20232023-06-0815,934,5645,999,4628,13272.65%Passed
20222022-06-0915,782,69711,179,894534,10958.54%Passed
20212021-06-1020,503,30910,933,5631,22565.22%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-07-1187.56%a
20242024-06-1197.47%b
20232023-06-0872.65%c

a. Voting standard not stated in the filing.

b. Approved under the standard stated in the filing — “If you ABSTAIN from voting on Proposal No. 3, the abstention will have no effect on the outcome of the proposal.”.

c. Approved under the standard stated in the filing — “If you ABSTAIN from voting on Proposal No. 3, the abstention will have the same effect as a vote AGAINST such proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Mary TagliaferriIndependent · Compensation · Not standing for re-election$31,301$116,954$454,242—$0$602,497
James I. HealyIndependent · Board Chair · Audit95,00041,975125,817—0262,792
David N. GillIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance82,50041,975125,817—0250,292
Laura J. HamillIndependent · Compensation (Chair) · Nominating and Corporate Governance70,00041,975125,817—0237,792
Ashutosh TyagiIndependent · Nominating and Corporate Governance60,00041,975125,817—0227,792
Johan Wedell-WedellsborgIndependent · Audit · Nominating and Corporate Governance (Chair)60,00041,975125,817—0227,792
Dr. Gérard BerIndependent · Departed during FY40,06100—040,061
Thomas GadEmployee director000—00
Michael RossiEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$438,862
Equity awards (grant-date value)$326,829
All other compensation$0
Total cost of the board$765,691

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Y-mAbs Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Y-mAbs Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Rhythm Pharmaceuticals, Inc.2025David Meeker$807,692$8,274,785$7,688,560$759,488$17,544,525
2SpringWorks Therapeutics, Inc.2024Saqib Islam760,0007,899,7606,689,100798,00016,153,317
3BioCryst Pharmaceuticals, Inc.2025Jon Stonehouse728,466011,132,4581,052,63312,951,082
4Arcus Biosciences, Inc.2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
5Travere Therapeutics, Inc.2025Eric Dube854,2503,314,5203,309,384964,1258,457,151
6Deciphera Pharmaceuticals, Inc.2023Steven Hoerter738,2001,935,0002,837,100487,2126,010,712
7Agios Pharmaceuticals, Inc.2025Brian Goff846,8641,291,6802,627,252592,8045,370,389
8Rigel Pharmaceuticals, Inc.2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
9Y-mAbs Therapeutics2024Michael Rossi705,6001,170,7322,288,662392,5964,557,590
10UroGen Pharma Ltd.2025Elizabeth Barrett855,5902,122,2110516,2634,310,624
11Heron Therapeutics, Inc.2025Craig Collard689,431946,2541,352,917517,1893,516,291
12Aadi Bioscience, Inc.2025David Lennon676,5041,318,907973,66403,359,075
13G1 Therapeutics, Inc.2023John Bailey794,9761,392,022666,209387,5513,250,658
14Puma Biotechnology, Inc.2025Alan Auerbach931,333551,549535,5131,027,3073,062,337
15bluebird bio, Inc.2023Andrew Obenshain681,657863,5901,142,440348,0243,049,181
16Karyopharm Therapeutics Inc.2025Richard Paulson770,000838,996241,544350,3502,320,902
17MacroGenics, Inc.2025Eric Risser561,56852,0001,049,386251,9002,078,854
18Iovance Biotherapeutics, Inc.2025Frederick Vogt800,000759,3750312,0001,888,175
19Atara Biotherapeutics, Inc.2025AnhCo Nguyen668,8000001,068,069

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Y-mAbs Therapeutics85.6%not disclosedNoAon
Aadi Bioscience, Inc.not disclosednot disclosednot disclosedRadford
Agios Pharmaceuticals, Inc.100%Option 40 · PSU 40 · RSU 20NoAon
Arcus Biosciences, Inc.100%Options 67 · RSU 33not disclosedRadford
Atara Biotherapeutics, Inc.not disclosedRSU 100not disclosedPearl Meyer
BioCryst Pharmaceuticals, Inc.not disclosednot disclosednot disclosedAon
bluebird bio, Inc.85%not disclosedYes — Relative Total Shareholder Return (rTSR)Aon plc (Human Capital Solutions practice)
Deciphera Pharmaceuticals, Inc.110%Option 50 · PSU 50 · RSU 25NoPearl Meyer & Partners, LLC
G1 Therapeutics, Inc.not disclosednot disclosednot disclosedRadford, Aon’s Human Capital Solutions Practice
Heron Therapeutics, Inc.not disclosedOption 66.67 · RSU 33.33not disclosedCompensia, Inc.
Iovance Biotherapeutics, Inc.60%not disclosedNoHaigh & Company
Karyopharm Therapeutics Inc.90%not disclosedYes — Relative TSRAlpine, WTW
MacroGenics, Inc.85%not disclosednot disclosedAlpine Rewards, LLC
Puma Biotechnology, Inc.169.7%Options 50 · RSU 50not disclosedCompensia
Rhythm Pharmaceuticals, Inc.120%Options 50 · RSU 50NoPay Governance
Rigel Pharmaceuticals, Inc.124%Options 75 · RSU 25NoPearl Meyer
SpringWorks Therapeutics, Inc.140%not disclosedYes — Relative Total Shareholder Return (TSR)Aon
Travere Therapeutics, Inc.150%not disclosedNoAon
UroGen Pharma Ltd.80%RSU 50 · PSU 50NoCompensia, Inc.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Y-mAbs Therapeutics in fiscal 2024?
As disclosed, Michael Rossi (President and Chief Executive Officer) was the highest-paid executive at Y-mAbs Therapeutics in fiscal 2024, with total compensation of $4,557,590.
How does Y-mAbs Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Michael Rossi's total compensation ranked at the 56th percentile of Y-mAbs Therapeutics's disclosed peer group.
How did shareholders vote on Y-mAbs Therapeutics's executive compensation?
As disclosed, 87.56% of shareholders supported Y-mAbs Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Y-mAbs Therapeutics spend in total on board compensation for fiscal 2024?
As disclosed, Y-mAbs Therapeutics reported total board compensation of $765,691 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Michael RossiDEF 14A2025-05-300001558370-25-008299Section “Executive Compensation”. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604
2Section 01, Peter PfreundschuhDEF 14A2025-05-300001558370-25-008299Section “Executive Compensation”. As printed: 2,504,717. Filing ↗machine: r11 · c23 · span 639226–639235
3Section 01, Thomas GadDEF 14A2025-05-300001558370-25-008299Section “Executive Compensation”. As printed: 2,075,163. Filing ↗machine: r8 · c23 · span 618762–618771
4Section 08, Mary TagliaferriDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 602,497. Filing ↗machine: span 1134969–1135142
5Section 08, James I. HealyDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 262,792. Filing ↗machine: span 1124739–1124912
6Section 08, David N. GillDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 250,292. Filing ↗machine: span 1121216–1121389
7Section 08, Laura J. HamillDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 237,792. Filing ↗machine: span 1128007–1128180
8Section 08, Ashutosh TyagiDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 227,792. Filing ↗machine: span 1131530–1131703
9Section 08, Johan Wedell-WedellsborgDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 227,792. Filing ↗machine: span 1138499–1138672
10Section 08, Dr. Gérard BerDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 40,061. Filing ↗machine: span 1115466–1115638
11Section 08, Thomas GadDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 0. Filing ↗
12Section 08, Michael RossiDEF 14A2025-05-300001558370-25-008299Section “Director Compensation”. As printed: 0. Filing ↗
13Section 02, Thomas Gad 2025-06-03Form 42025-06-050001415889-25-015849Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, Thomas Gad 2025-06-03Form 42025-06-050001415889-25-015849Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Ashutosh Tyagi 2025-06-30Form 42025-07-020001415889-25-019049Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Ashutosh Tyagi 2025-06-30Form 42025-07-020001415889-25-019049Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, James I. Healy 2025-06-30Form 42025-07-020001415889-25-019047Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, James I. Healy 2025-06-30Form 42025-07-020001415889-25-019047Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Laura J. Hamill 2025-06-30Form 42025-07-020001415889-25-019050Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Johan Wedell-Wedellsborg 2025-06-30Form 42025-07-020001415889-25-019048Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Johan Wedell-Wedellsborg 2025-06-30Form 42025-07-020001415889-25-019048Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, David N. Gill 2025-06-30Form 42025-07-020001415889-25-019046Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, David N. Gill 2025-06-30Form 42025-07-020001415889-25-019046Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Laura J. Hamill 2025-06-30Form 42025-07-020001415889-25-019050Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, John LaRocca 2025-09-16Form 42025-09-180001732197-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, John LaRocca 2025-09-16Form 42025-09-180001732197-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, John LaRocca 2025-09-16Form 42025-09-180001732197-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Johan Wedell-Wedellsborg 2025-09-16Form 42025-09-180001753185-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Douglas J. Gentilcore 2025-09-16Form 42025-09-180002052524-25-000003Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Biotech ApS WG 2025-09-16Form 42025-09-180001753193-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Ashutosh Tyagi 2025-09-16Form 42025-09-180001752467-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Joris Wilms 2025-09-16Form 42025-09-180001753231-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Michael Rossi 2025-09-16Form 42025-09-180001948795-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Thomas Gad 2025-09-16Form 42025-09-180001753224-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Laura J. Hamill 2025-09-16Form 42025-09-190001751804-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Peter Pfreundschuh 2025-09-16Form 42025-09-180001585839-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Peter Pfreundschuh 2025-09-16Form 42025-09-180001585839-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Peter Pfreundschuh 2025-09-16Form 42025-09-180001585839-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Peter Pfreundschuh 2025-09-16Form 42025-09-180001585839-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Peter Pfreundschuh 2025-09-16Form 42025-09-180001585839-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, David N. Gill 2025-09-16Form 42025-09-180001106519-25-000005Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, James I. Healy 2025-09-16Form 42025-09-180001245624-25-000004Insider equity transaction reported since the proxy statement. Filing ↗
127Section 06, 2025 voteForm 8-K2025-07-150001104659-25-068099Item 5.07 · say-on-pay result. As reported: 87.56% (votes for as printed: 27,011,027). Filing ↗
128Section 06, 2024 voteForm 8-K2024-06-130001104659-24-071250Item 5.07 · say-on-pay result. As reported: 97.47% (votes for as printed: 27,772,834). Filing ↗
129Section 06, 2023 voteForm 8-K2023-06-090001104659-23-070029Item 5.07 · say-on-pay result. As reported: 72.65% (votes for as printed: 15,934,564). Filing ↗
130Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
131Section 09b board cost (computed)Computed——Cash 438,862 + equity 326,829 + all other 0 = 765,691, summed across the director compensation table rows.machine: formula: Σ = 765,691
132Rhythm Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-290001628280-26-028375CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074
133SpringWorks Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-040001104659-25-032187CEO total compensation as printed in SpringWorks Therapeutics, Inc.'s own proxy. As printed: 16,153,317. Filing ↗machine: r1 · c47 · span 623184–623194
134BioCryst Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in BioCryst Pharmaceuticals, Inc.'s own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
135Arcus Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences, Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749
136Travere Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-060001438533-26-000027CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523
137Deciphera Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2024-04-250001654151-24-000012CEO total compensation as printed in Deciphera Pharmaceuticals, Inc.'s own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895
138Agios Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177086CEO total compensation as printed in Agios Pharmaceuticals, Inc.'s own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194
139Rigel Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-030001034842-26-000023CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068
140Y-mAbs Therapeutics (subject), Section 10b CEO totalDEF 14A2025-05-300001558370-25-008299CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: r5 · c23 · span 597595–597604
141UroGen Pharma Ltd., Section 10b CEO totalDEF 14A2026-04-300001437749-26-014237CEO total compensation as printed in UroGen Pharma Ltd.'s own proxy. As printed: 4,310,624. Filing ↗machine: r1 · c29 · span 562926–562935
142Heron Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-196306CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221
143Aadi Bioscience, Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187149CEO total compensation as printed in Aadi Bioscience, Inc.'s own proxy. As printed: 3,359,075. Filing ↗machine: r2 · c29 · span 462559–462568
144G1 Therapeutics, Inc., Section 10b CEO totalDEF 14A2024-04-250001193125-24-113902CEO total compensation as printed in G1 Therapeutics, Inc.'s own proxy. As printed: 3,250,658. Filing ↗machine: r3 · c31 · span 348805–348814
145Puma Biotechnology, Inc., Section 10b CEO totalDEF 14A2026-04-280001437749-26-013671CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. Filing ↗machine: t56 · r1 · c29 · span 540970–540979
146bluebird bio, Inc., Section 10b CEO totalDEF 14A2024-09-260001293971-24-000049CEO total compensation as printed in bluebird bio, Inc.'s own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796
147Karyopharm Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-130001503802-26-000023CEO total compensation as printed in Karyopharm Therapeutics Inc.'s own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348
148MacroGenics, Inc., Section 10b CEO totalDEF 14A2026-04-080001125345-26-000021CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198
149Iovance Biotherapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050458CEO total compensation as printed in Iovance Biotherapeutics, Inc.'s own proxy. As printed: 1,888,175. Filing ↗machine: r6 · c16 · span 797910–797919
150Atara Biotherapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177285CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. Filing ↗machine: span 714260–714269
151Section 10a, Atara Biotherapeutics, Inc. reciprocityDEF 14A—0000950170-25-059322Atara Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
152Section 10a, Agios Pharmaceuticals, Inc. reciprocityDEF 14A—0001193125-26-177086Agios Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
153Section 10a, G1 Therapeutics, Inc. reciprocityDEF 14A—0001193125-24-113902G1 Therapeutics, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
154Section 10a, Iovance Biotherapeutics, Inc. reciprocityDEF 14A—0001104659-26-050458Iovance Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
155Section 10a, BioCryst Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-026822BioCryst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
156Section 10a, Deciphera Pharmaceuticals, Inc. reciprocityDEF 14A—0001654151-24-000012Deciphera Pharmaceuticals, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
157Section 10a, Heron Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-196306Heron Therapeutics, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
158Section 10a, Karyopharm Therapeutics Inc. reciprocityDEF 14A—0001503802-26-000023Karyopharm Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
159Section 10a, MacroGenics, Inc. reciprocityDEF 14A—0001125345-26-000021MacroGenics, Inc. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗
160Section 10a, Puma Biotechnology, Inc. reciprocityDEF 14A—0001437749-26-013671Puma Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
161Section 10a, Rhythm Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-028375Rhythm Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
162Section 10a, Rigel Pharmaceuticals, Inc. reciprocityDEF 14A—0001034842-26-000023Rigel Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
163Section 10a, SpringWorks Therapeutics, Inc. reciprocityDEF 14A—0001104659-25-032187SpringWorks Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
164Section 10a, Travere Therapeutics, Inc. reciprocityDEF 14A—0001438533-26-000027Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Y-mAbs Therapeutics. Filing ↗
165Section 10a, UroGen Pharma Ltd. reciprocityDEF 14A—0001437749-26-014237UroGen Pharma Ltd. names Y-mAbs Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.